14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
MTVA vs STRO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Sutro Biopharma, Inc. (STRO) is the stronger overall head-to-head candidate over MetaVia Inc. (MTVA) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale). MTVA carries a Unified Composite Score of 48.0/100 (HOLD) at $1.01 (N/M Forward P/E, 0.0% operating margin), whereas STRO carries 44.1/100 (HOLD) at $8.60 (10.0x Forward P/E, -254.7% operating margin).
Composite vs. Pillar Nuance: While MTVA currently prints a higher short-term Unified Composite Score (48.0/100 HOLD vs. STRO 44.1/100 HOLD), STRO captures the overall institutional head-to-head verdict (5–4 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (-254.7% vs. 0.0% operating margin) and revenue trajectory (-6.1% vs. +0.0% YoY).
Technical & Structure Timing Caution: MTVA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.1); meanwhile STRO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MTVA vs STRO. Trailing 12-month operating profitability (MTVA 0.0% vs STRO -254.7%) and valuation multiples (MTVA N/M vs STRO 10.0x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $144.8M market capitalization and -254.7% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ MTVA vs STRO Key Questions & Quantitative Answers
As of Nov 20, 2026, Sutro Biopharma, Inc. (STRO) is the stronger overall head-to-head candidate over MetaVia Inc. (MTVA) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale). MTVA carries a Unified Composite Score of 48.0/100 (HOLD) at $1.01 (N/M Forward P/E, 0.0% operating margin), whereas STRO carries 44.1/100 (HOLD) at $8.60 (10.0x Forward P/E, -254.7% operating margin). Composite vs. Pillar Nuance: While MTVA currently prints a higher short-term Unified Composite Score (48.0/100 HOLD vs. STRO 44.1/100 HOLD), STRO captures the overall institutional head-to-head verdict (5–4 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (-254.7% vs. 0.0% operating margin) and revenue trajectory (-6.1% vs. +0.0% YoY). Technical & Structure Timing Caution: MTVA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.1); meanwhile STRO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
STRO leads the Growth & Scale pillar: MTVA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with STRO at -6.1% YoY revenue growth and +0.0% YoY earnings growth on $45M TTM revenue (N/A gross margin, -254.7% operating margin). On trailing 12-month operating scale, MTVA generates N/A in USD-normalized revenue versus $45M for STRO. In operating R&D and SG&A reinvestment, MTVA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for STRO.
STRO screens cheaper on headline valuation multiples. MTVA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas STRO trades at 10.0x Forward P/E, 10.0x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MTVA (-175.7% ROE) versus STRO (-1810.0% ROE) capital efficiency.
In options market volatility and institutional positioning, MTVA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.30β · 166% Vol realized risk). By comparison, STRO carries 122.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.46β · 76% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.